Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia

Annals of Oncology

Volumn 14, Issue 5, 2003, Pages 752-757

  Au, W Y ^a   Lie, A K W ^a   Chim, C S ^a   Liang, R ^a   Ma, S K ^a   Chan, C H ^b   Mak, Y K ^b   Chen, Y T ^b   So, C C ^b   Yeung, Y M ^c   Yip, S F ^c   Wong, L G ^c   Chan, J C ^d   Liu, S Y ^d   Kwong, Y L ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c TUEN MUN HOSPITAL   (Hong Kong)

^d PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

Author keywords

Acute promyelocytic leukaemia; Allogeneic bone marrow transplantation; Arsenic trioxide; Relapse

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLEEDING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DRUG HYPERSENSITIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HONG KONG; HOSPITAL; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SALVAGE THERAPY; SEPSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0038781797     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg208     Document Type: Article

References (20)

1. Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177-189.
2. 3 exerts dose-dependent dual effect on APL cells in vitro and in vivo. Blood 1997; 89: 3345-3353.
3. Head D, Kopecky KJ, Weick J et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995; 86: 1717-1728.
4. Cunningham I, Gee TS, Reich LM et al. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989; 73: 1116-1122.
5. Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13-25.
6. Kwong YL, Wong KF, Chan TK. Trisomy 8 in acute promyelocytic leukaemia: an interphase study by fluorescence in situ hybridization. Br J Haematol 1995; 90: 697-700.
7. Kwong YL, Au WY, Chim CS et al. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001; 66: 274-279.
8. Au WY, Chim CS, Lie AKW et al. Combined arsenic trioxide and all trans retinoic acid treatment for acute promyelocytic leukemia recurring from previous relapses successfully treated by arsenic trioxide. Br J Haematol 2002; 117: 130-132.
9. Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13-25.
10. Sanz MA, Lo Coco F, Martin G et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
11. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
12. Chiu EK, Chan LC, Liang R et al. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect. Leukemia 1994; 8: 1469-1473.
13. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-767.
14. Cortes JE, Kantarjian H, O'Brien S et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994; 73: 2946-2952.
15. Thomas X, Anglaret B, Thiebaut A et al. Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy. Ann Hematol 1997; 75: 195-200.
16. Meloni G, Diverio D, Vignetti M et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997; 90: 1321-1325.
17. Thomas X, Dombret H, Cordonnier C et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. Leukemia 2000; 14: 1006-1013.
18. Zanz MA, Arcese W, de la Rubia J et al. Stem cell transplantation (SCT) for acute promyelocytic leukemia (APL) in the ATRA era: a survey of the European Blood and Marrow Transplantation Group (EBMT). Blood 2000; 96: (Abstr 2247).
19. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
20. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.